MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).

Authors: Alexander M. Lesokhin, Jonathan L. Kaufman, Ashraf Badros, Jorge Acosta, Patrick Muller, Carolyn Lou, Ashleigh O'Connell, Gabriel Afram, Attaya Suvannasankha

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps7566

Source: Full article

---

Abstract

TPS7566